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Summary The aim was to perform a broad phase 11 and pharmacokinetic study of methoxymorpholino-doxorubicin (MMRDX), a drug active
against multidrug-resistant tumour cells in vitro when given by i.v. bolus at 1.5 mg m-2 every 4 weeks, in metastatic or unresectable solid
tumour patients with known intrinsic drug resistance. Patients received a maximum of six cycles. Plasma, urine and leucocyte MMRDX and
its 13-dihydro metabolite pharmacokinetic analysis was performed in patients without liver metastases. Patients (n = 48, 21 NSCLC, 19 renal
cell, three head and neck tumour, three cervical cancer and two adenocarcinoma of unknown primary) received 132 cycles of MMRDX.
Common toxicity criteria (CTC) grade III/IV thrombocytopenia (12% of cycles) and neutropenia (27% of cycles) occurred with median nadir on
day 22. Transient transaminases elevation 2 grade III/IV was observed in 7% of cycles, late and prolonged nausea 2 grade 11 in 34% and
vomiting . grade 11 in 39%. In two patients, the left ventricular ejection fraction was reduced 2 15%. Of 37 evaluable patients, one out of 17
NSCLC had a partial response. Mean (± s.d.) MMRDXAUCo, calculated up to 24 h after dosing was 20.4 ± 6.2 ,ug h 1-' (n = 11) andtf/2,3 was
44.2 h. Mean plasma clearance (± s.d.) was 37.2 ± 7.3 h-' m-2 and volume of distribution 1982 ± 64 m-2. MMRDX leucocyte levels
2 and 24 h after infusion were 450 to 600-fold higher than corresponding MMRDX plasma levels. In urine, 2% of the MMRDX dose was
excreted unchanged, and 2% as metabolite. The main side-effects of 1.5 mg m-2 every 4 weeks of MMRDX are delayed nausea and vomiting
and haematological toxicity. MMRDX is characterized by extensive clearance and rapid and extensive distribution into tissues. A low
response rate was observed in patients with tumours with intrinsic chemotherapy resistance.
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After their introduction into clinical practice in the 1960s, anthra-
cyclines have gained a major place in curative and palliative
chemotherapeutic cancer treatment with activity in a wide
spectrum of neoplasms. Limitations of the clinical value of
anthracyclines are their toxicity profile, especially irreversible,
dose-related cardiotoxicity, and intrinsic or acquired tumour resis-
tance. Various mechanisms play a role in tumour cell resistance to
anthracyclines, including overexpression of drug efflux pumps
such as P-glycoprotein, decreased levels of the target enzyme
topoisomerase II, and an increase in cellular detoxifying capacity
(Kaye and Merry, 1985; Deffie et al, 1989; De Jong et al, 1990;
Ford and Hait, 1990; Meijer et al, 1990; Zaman et al, 1994). The
morpholinyl anthracyclines have been developed in the course of
research aimed at identifying new anthracyclines with at least
partially novel modes ofaction in addition to activity against resis-
tant tumours (Acton et al, 1984). The morpholinyl anthracyclines
possess a morpholino ring incorporating the amino nitrogen at the
3'-position of the daunosamine unit of the anthracycline molecule
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(Figure 1). This modification of the molecule increases
lipophilicity and hence facilitates cellular uptake. Compared with
other anthracyclines, morpholinyl anthracyclines appeared potent
inhibitors of ribosomal gene transcription and were found to
inhibit RNA synthesis in a fundamentally different way (Johnston
and Glazer, 1983; Wasserman et al, 1988; Grandi et al, 1990).
Unlike other anthracyclines, the morpholinyl derivates have been
found to cause DNA damage not through stabilization of topoiso-
merase II-induced double-strand breaks but through topoiso-
merase I single-strand breaks (Wasserman et al, 1990). In vivo the
morpholinyl anthracyclines are activated to highly potent
metabolite(s) by cytochrome P450 (Streeter et al, 1986; Lau et al,
1989; Lewis et al, 1992; Ripamonti et al, 1992). Morpholinyl
anthracyclines show no cross-resistance in doxorubicin-resistant
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Figure 1 Chemical structures of doxorubicin and MMRDX
139140 MBakker etal
Table 1 Pretreatment patient characteristics
Number of patients
Age median (range)
Years
Performance score (ECOG)
0
1
2
Tumour type
NSCLC
Renal
Cervix
Head and neck
ACUP
Pretreatment
Radiotherapy
Radio- + immunotherapy
Radio- + chemotherapy
Chemotherapy
Immunotherapy
None
Liver metastases
48
56 (33-73)
12
32
4
21
19
3
3
2
5
1
2
0
9
31
10
Table 2 Cycles (%) with haematological toxicity (n = 126)
CTC
Grade I Grade II Grade IlIl Grade IV
(%) (%) (%) (%)
Leucopenia 17 23 19 6
Neutropenia 13 20 18 9
Thrombocytopenia 11 6 6 6
Anaemia 37 31 5 0
Table 3 Median (range) nadir blood cell counts
Leucocytes Neutrophils Platelets Haemoglobin
(X 109,1-1) (X 1091-1) (X 1091-') (g l-1)
Cycle 1 3.0 (0.1-9.1) 1.4 (<0.1-5.8) 178 (8-449) 110(69-147)
n=47 n=47 n=47 n=47
Cycles 2-6 3.0 (0.1-9.8) 1.7 (< 0.1-6.8) 117 (9-372) 103 (69-153)
n=82 n=81 n=80 n=82
P-glycoprotein-positive and multidrug resistance-associated
protein positive cell lines (Streeter et al, 1986; Coley et al, 1989;
Coley et al, 1991; Danesi et al, 1993), cell lines with an altered
topoisomerase II and cell lines resistant to cisplatin and melphalan
(Grandi et al, 1990; Ripamonti et al, 1992; Van der Graaf et al,
1995). Methoxymorpholino doxorubicin (MMRDX) might, there-
fore, be a potentially attractive drug in the treatment of tumours
with intrinsic and acquired anthracycline resistance. In vivo
studies with MMRDX showed an 80- to 150-fold increase in
potency compared with doxorubicin in murine leukaemias. In
solid tumours in animal models, MMRDX was found to be as
effective as doxorubicin, with similar activity when administered
by the intraperitoneal, the intravenous (i.v.) or the oral route
(Grandi et al, 1990; Ripamonti et al, 1992). In contrast to all other
anthracyclines, morpholinyl anthracyclines were not cardiotoxic
in an animal model at therapeutically effective anti-tumour doses
(Acton et al, 1984; Danesi et al, 1993). The promising anti-tumour
activity in cell lines and in animal models, the novel mode of
action and the absence of cardiotoxicity justified clinical explo-
ration. In a phase I study the maximum-tolerated dose was estab-
lished at 1.5 mg m-2 by i.v. bolus every 3 weeks, with toxicity
mainly consisting of late neutropenia, late thrombocytopenia, late
vomiting and prolonged nausea as well as transient liver toxicity
(Vasey et al, 1995). Because bone marrow toxicity was dose
limiting with late nadir counts at day 22 for neutrophils and
platelets, this study was initiated at the maximum-tolerated dose
with a longer treatment interval.
A broad phase II study with MMRDX 1.5 mg m-2 i.v. bolus
every 4 weeks was performed in tumours usually considered to be
resistant to chemotherapy, including anthracyclines. The anti-
tumour activity of the compound was evaluated and a pharmaco-
kinetic study was performed in conjunction with the analysis of
cellular levels ofMMRDX.
PATIENTS AND METHODS
Patients
Patients were accrued from eight participating centres in five
different countries. The aim was to include at least 20 patients
evaluable fortoxicity afterthree cycles. Patients who were eligible
for this study were not amenable to curative treatment, with
measurable or evaluable lesions of metastatic or locally advanced
non-small-cell lung cancer (NSCLC), head and neck, colorectal,
renal, cervix cancer or adenocarcinoma of unknown origin
(ACUP). Previous chemotherapy was only allowed as adjuvant
treatment for colorectal cancer and radiosensitization for head and
neck and cervix cancerpatients, provided that these treatments had
been finished more than 12 months and 6 weeks before treatment
respectively. Previous radiotherapy was allowed if less than 25%
of the bone marrow had been irradiated. Additional inclusion
criteria were age . 18 and < 75 years, Eastern Cooperation
Oncology Group (ECOG) performance score < 2 (Miller et al,
1981), life expectancy 2 3 months, neutrophils . 2.0 x 109 1-1,
platelets 2 150 x 109 1-1, serum creatinine < 1.25 times the upper
limit value of the institution, serum bilirubin, alkaline phos-
phatase, aspartate aminotransferase (ASAT) and alanine amino-
transferase (ALAT) within the normal limits of the institution. In
case of liver metastases, patients were eligible if bilirubin was
normal and alkaline phosphatase, ASAT and ALAT were < 2.5
times the upper normal limit of the institution. Patients with brain
or leptomeningeal disease, active infectious process, previous or
concurrent malignancies at other sites (with the exception of in
situ carcinoma ofthe cervix and basal or squamous cell carcinoma
of the skin), myocardial infarction within the last 12 months, left
ventricular ejection fraction (LVEF) below the lower normal
institutional limit as measured by echocardiography or multiple
electrocardiogram (ECG)-gated radionuclide study (MUGA-
scan), arrhythmias requiring permanent medication, uncontrolled
hypertension, ischaemic heart disease, or previous anthracycline
treatment were ineligible. Approval from the Medical Ethics
Committee was obtained in all participating institutions, and all
patients gave written informed consent before entry into the study.
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Figure 2 Average MMRDX and 13 dihydro metabolite plasma
concentrations and average MMRDX concentrations in leucocytes
(mean ± s.d.).., MMRDX in leucocytes.0.MMRDX in plasma; A,
13-dihydro metabolite in plasma
Table 4 Percentage of cycles with non.haematological toxicity (on 132
evaluable cycles)
CTC
Grade I Grade MR Grade III Grade IV
conentatins ndvergeMMD cocnrain in leccye
Nausea 43 27 7
Vomiting 24 30 4 5
Stomatitis 11 1 1 0
Diarrhoea 7 1 1 0
Liver
ASAT 46 16 2 0
ALAT 37 27 7 0
Bilirubin - 12 0 1
Fatigue/malaise 24 22 7 5
Alopecia 10 1.5 -
Before treatment all patients underwent baseline measurements for
blood counts and liver, renal and cardiac function. Baseline LVEF
was measured by MUGA scan or echocardiography. Staging
procedures included physical examination, chest radiograph and
ultrasound of the abdomen or computerized tomogaphy (CT) scan
of either chest or abdomen. Additional tests such as bone scintig-
raphy were performed when metastases were suspected.
Treatment
MMRDX 1.5 mg m-2 (supplied by Pharmacia, Milan, Italy) was
prepared by dissolving 50 or 500 gg vials in 5 ml of 0.9% sodium
chloride and administered on day 1 in the outpatient clinic as a 2-
3 min i.v. push every 4 weeks, with a maximum ofsix cycles oruntil
disease progression. Treatment of the next cycle was postponed in
case of incomplete recovery of any toxicity, except alopecia. Dose
reduction to 1.25 mg m-2 MMRDX was performed for grade IV
neutropenia lasting morethan 8 days, febrile neutropenia, grade 2 III
Table 5 Compartmental plasma pharmacokinetic parameters of MMRDX
obtained during the first treatment cycle in 11 patients
Parameter Mean ± s.d.
t'12,(" 0.069 ± 0.147 (h)
t,,2 a 2.42 ± 1.04 (h)
t'12,Y 49.2 ± 20.2 (h)
AUCO^ 20.4 ± 6.2 (,ug x h 1-')
Clearance 37.2 + 7.3 (I h-1 m-2)
V. 34.9 ± 32.5 (I m-2)
V.. 1983±611 (Im-2)
1z 2507± 808 (I m-2)
infection requiring i.v. antimicrobial drugs, grade 2 III platelet toxi-
city, as well as neutrophils <2 x 1091-1 orplatelets < 150 x 1091-1 on
day 28. In addition, the MMRDX dose was reduced whenevergrade
IIbilirubin orgrade IASAT orALATtoxicity persisted onday 28. If
the same toxicity occurred at 1.25 mg m-2, MMRDX treatment was
discontinued. MMRDX treatment was also discontinued in cases of
grade IV anaemia, grade > III renal toxicity, grade . HI bilirubin or
grade IV aminotransferase toxicity, any combination of grade III
and/or grade IV clinical toxicities (anorexia excluded), grade 2 II
neurological toxicity, incomplete bone marrow recovery on day 42
(including platelets 2 150 x 109 but still descending) or cardiotoxi-
city (defined as clinical signs ofcongestive heart failure or a decline
ofLVEF . 20% to avalue above the lower limit ofthe institution or
2 10% to a value below the lower normal limit). Intensive prophy-
lactic treatment for nausea and vomiting was administered in a
centre-dependent schedule.
Toxicity
Toxicity was weekly (day 1-14) and twice weekly (day 15-28)
graded according to the National Cancer Institute Common
Toxicity Criteria (CTC). Blood chemistry including renal function
and liver enzymes was performed before each drug administration;
hepatic enzymes and bilirubin were measured weekly; in particular,
ASAT and ALAT were evaluated on day 3 of the first cycle.
Complete blood cell counts and differential were performed on day
7 and twice weekly after day 14 ofeach cycle. Evaluation ofLVEF
by echocardiogram or MUGA was repeated every two cycles
starting from the fourth course. After discontinuation of the study,
all clinical andlaboratory parameters were repeated every 3 months
until disease progression or the start of a new anti-tumoral therapy.
Response measurement
Tumour measurements according to WHO criteria (World Health
Organization, 1979) were performed before therapy, after the third
and last cycle and repeated thereafter every 3 months. Complete
response was defined as the disappearance of all known disease,
determined by two observations not less than 4 weeks apart. A
partial response was defined as a decrease by 50% or more in the
sum ofthe product ofthe two largest perpendicular diameters ofall
measurable lesions, as determined by two consecutive observa-
tions not less than 4 weeks apart. Less than 50% decrease or less
than 25% increase in total tumour size, persisting for at least 4
weeks, was defined as stable disease. Progressive disease was
defined as 2 25% increase in the size of one or more measurable
lesions or the appearance of new lesions.
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Pharmacokinetics
Only patients with age < 65 years and no liver metastases were
included in the pharmacokinetic study. Patients were hospitalized
for the first day of cycle 1. Plasma, urine and leucocyte samples
for pharmacokinetic analysis were collected in cycle 1 during the
first 96 h. All samples were protected from light because of the
photosensitivity of MMRDX. Blood samples (8 ml) were
collected from the contralateral arm in heparinized glass tubes
before MMRDX injection, at the end ofthe i.v. bolus and at 5, 10,
15, 30 and 45 min, and at 1, 2, 4, 6, 8, 10, 24, 48, 72 and 96 h
thereafter. The blood was immediately centrifuged at 1200g for
10 min at4°C and the plasma was stored in polypropylene tubes at
-20°C until the time ofanalysis.
Blood samples drawn before, and at 2 and 24 h after MMRDX
injection were also used for MMRDX measurements in leuco-
cytes. Leucocytes were isolated from whole blood by adding
lysing solution (O.15 M ammonium chloride, 1O mm potassium
bicarbonate, 0.11 mm dipotassium EDTA) to the blood cells
collected after 10-min centrifugation (150g) at 40C. This proce-
dure was repeated until the cell pellet was apparently free of
erythrocytes. Leucocytes were resuspended with 250 gl of phos-
phate-buffered saline (0.14 M sodium chloride, 2.7 mm potassium
chloride, 6.4 mm disodium hydrogen phosphate dihydrate, 1.5 mM
potassium dihydrogen phosphate), counted and stored at -200C
until analysis. Urine was sampled before MMRDX administration
and collected up to 96 h after the start of the treatment as 24 h
samples in lightprotectedplastic bottles. The volume and pH were
measured and the 24-h urine was stored as 30-ml samples at-200C
in polypropylene tubes.
MMRDX and its 13-dihydro metabolite (FCE 26176, 13-
dihydro-3'-deamino-3'-[2(S)-methoxy-4-morpholinyl] doxoru-
bicin) were determined in plasma, leucocyte and urine samples
usinghigh-performance liquidchromatography (HPLC) with fluo-
rescence detection according to Breda et al (1992). Briefly, 200 ,l
of daunomycin (internal standard) 38 nM (Pharmacia) was added
to 1 ml of plasma buffered with 0.5 ml of 0.1 M borate at pH 8.4.
After the addition of 4 ml of diethylether-n-butanol mixture (9:1,
v/v) the sample was vortexed for 1 min and centrifuged (1600g,
3 min). After 3 min at -53'C the upper organic layer was trans-
ferred to a silanized glass tube. Thereafter, the extraction proce-
dure was repeated. Phosphoric acid (250gl, 0.05 M) was added to
the combined organic phases, vortexed for 1 min, centrifuged
(1600g for 3 min) and placed at -530C for 3 min. The organic
phase was discarded and the acidic phase was washed with 0.5 ml
n-hexane by 1-min vortexing, spun (1600g) for 3 min, and then
placed at -53°C for 3 min. The n-hexane was removed and 200gl
aqueous solution was injected onto the HPLC column. The HPLC
system used for the determination ofMMRDX and the 13-dihydro
metabolite consisted of a pump (model 6200A, Merck Hitachi,
Darmstadt, Germany), a refrigerated (80C) autosampler (model
717 plus, Waters, Milford, MA, USA), a fluorometric detector
(fluorometer RF 551, Shimadzu, Kyoto, Japan) equipped with a
dedicated photomultiplier (model R3896, Shimadzu) and an inte-
grating system (Chromjet integrator with Winner on Windows,
TSP, San Jose, CA, USA). The fluorometric detector was set at
495/556 nm (excitation/emission wavelength). The chromato-
graphic separation was performed using a 150 x 4.6 mm i.d.
Hypersil C18 column (particle size 3 gm, Alltech, Deerfield, IL,
USA) equipped with a precolumn filled with pellicular octadecyl-
silane (ODS) (particle size 37-53 jm, Whatman, Clifton, NJ,
USA). The mobile phase consisted of 50 mM potassium di-
hydrogen phosphate (adjusted to pH 2.7 with phosphoric
acid)-acetonitrile-tetrahydrofuran (72:18:10, v/v); the separation
was performed at a flow rate of 1 ml min-'. The analytical proce-
dure used to detect MMRDX and its metabolite in urine was the
same reported above for plasma with minor modifications: 0.5 M
instead of 0.1 M borate buffer, and 500 jl instead of 250 jl of
phosphoric acid were used; in addition, washing ofthe acidic phase
was performed with 1 ml instead of 0.5 ml of n-hexane. The
analytical procedure was slightly modified to detect MMRDX and
13-dihydro metabolite in leucocytes as follows: after defrosting,
leucocytes were separated from the supernatant using centrifuga-
tion (150g) at 4°C and resuspended in 1 ml ofphosphate-buffered
saline. An aliquot (100) jil of 0.038 jM internal standard was
added instead of 200 jil, and the suspension was exposed to ultra-
sonic vibration for 10 minbefore extraction. Otherwise, the analyt-
ical procedure was identical to the urine detection procedure.
The quantitation limits for MMRDX were, respectively,
0.1 jg 1-1 (plasma) and 0.5 jig 1- (urine and leucocytes); for
13-dihydro metabolite 0.1jIg 1-1 in plasma, and 0.5 and 0.5 jig 1-1
in leucocytes and urine respectively.
Data analysis
Pharmacokinetic data analysis was performed with the Sipharphar-
macokinetic package (Siphar Users Manual, version 4.0, 1991).
MMRDX plasma concentration vs time curves were first inter-
preted in terms of compartmental models. Considering the very
short half-life of the first phase, the duration of the administration
was not negligible; therefore, the administration was considered in
the model as a short infusion with the duration equal to the indi-
vidual infusion duration (range 2-8 min). The choice ofthe model
was based on graphic judgement and using Akaike Information
Criteria (Akaike, 1974). Multiexponential equations were fitted to
the data with weighted non-linear regression analysis (weight
1/y2calc' whereycalc is the predictedconcentration). Owing to the low
and erratic plasma concentrations of the 13-dihydro metabolite,
only non-compartmental analysis was performed for the metabo-
lite. Haematological and non-haematological toxicity were tenta-
tively correlated to descriptors of plasma and leucocyte
pharmacokinetics using a modification of the Hill equation
(Wagner, 1968). Haematological toxicity was expressed as absolute
(nadir) and relative decrease in neutrophils, leucocytes or platelets.
The relative decrease in blood cell counts was calculated as
[(pretreatment value - nadir value) / pretreatment value] x 100%.
The plasma pharmacokinetic parameters were AUC and Cmax; the
cellular parameter was the measured concentration. Non-haemato-
logical toxicity was evaluated according to CTC grading.
RESULTS
Between June and October 1994, 49 patients were entered in the
study (22 NSCLC, 19 renal cell, three head and neck tumours,
three cervical cancers and two ACUP). One patient with NSCLC
refused treatment after inclusion into the study. Patient characteris-
tics at start of treatment are summarized in Table 1. Most patients
(65%) had not received any previous anti-cancer therapy. During
the present study, eight patients received one cycle, 14 patients
two cycles, 16 patients three cycles, six patients four cycles and
four patients received 6 cycles MMRDX. The total number of
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cycles was 132 with a median ofthree perpatient (range 1-6). The
treatment was discontinued for progressive disease in 29, toxicity
in ten, intercurrent illness in one and death in four (three deaths
because ofprogressive disease and one septic death) and refusal in
one patient. A total of 84% of the cycles were fully dosed.
Received dose intensity (RDI) divided by projected dose intensity
(PDI, 1.5 mg m-2 every 4 weeks) by cycle was 1, 0.97, 0.89, 0.86,
0.83 and 0.84, respectively, for the first and the subsequent
five cycles.
Toxicity
Forty-seven patients were evaluable for haematological toxicity;
26 patients were evaluable for at least three cycles. Grade IIIIIV
neutropenia was the most common haematological toxicity (Table
2). MMRDX induced late bone marrow toxicity. The median
neutrophil nadir occurred at day 22 (range 6-36) (see Table 3 for
nadirs). The median time to recovery from nadir to > 2 x 109 1-'
was 7 days (range 2-22) and the median duration (range) ofgrade
IV neutropenia was 7 days (1-14). Seven patients were hospital-
ized for neutropenic fever and one patient for grade IV infection
associated with grade II neutropenia; all patients recovered except
one. This patient, who had renal cancer with lung and adrenal
lesions and diabetes mellitus, experienced grade III neutropenia,
grade II thrombocytopenia and grade III hyperglycaemia in the
first cycle. The second, delayed but unreduced, cycle was compli-
cated by grade IV neutropenia, leucopenia and thrombocytopenia,
grade III anaemia andhyperglycaemia. This patient died onday 14
ofcycle 2 as a result ofsepsis.
Platelet nadir occurred at day 22 (range 7-36). The median time
to recovery from nadir to > 100 x 1091-' was 7 days (range 1-20);
the median duration of grade IV thrombocytopenia was 11 days
(range 3-19). In one cervical carcinoma patient, grade III vaginal
bleeding necessitated embolization on day 14 of cycle 2, with a
platelet count of48 x 1091-'.Thisbleeding was supposedly because
of tumour necrosis. The total number of hospital admissions for
haematological toxicity was eight (excluding admission for blood
cell transfusion). Dose adjustments for haematological toxicity
were necessary in eight patients in 19% of cycles; 29% of cycles
had to be delayed and one patient had to be taken off-study for
haematological toxicity. Bone marrow toxicity was variable. No
predictive factor could be found forgrade III/IV bone marrow toxi-
city observed in cycle 1 in previously untreated patients. In two
patients who had received some form ofchemotherapeutic pretreat-
ment, MMRDX treatment was associated with grade III/IV haema-
tological toxicity. Previous radiotherapy and/or immunotherapy,
however, was not associated with serious bone marrow toxicity. In
26 patients who received at least three cycles, mild cumulative
toxicity was observed only for platelet counts with median nadirs
of 178x 1091-'in cycle l and 145, 108, 106, 90 and 117x 1091-'for
the following cycles. Neither liver metastases nor liver function
tests appeared to be predictive factors for haematological toxicity.
Table 4 shows the non-haematological toxicity. Despite intensive
prophylactic antiemetic treatment, nausea and vomiting were
frequently observed (100 out of 131 and 82 out of 131 cycles
respectively). Twenty-nine patients received prophylactically i.v.
dexamethasone plus ondansetron with or without oral alizapride,
whereas 18 received oral domperidone maleate with or without
ondansetron, metoclopramide, alizapride plus methylprednisolone.
In cases of persisting nausea and vomiting after prophylactic
treatment, patients were treated with metoclopramide chloride
20 mg suppositoria 1-6 times per day. The median day of onset of
nausea was day 3 (range 1-17), with a median duration of 7 days
(range 1-38). For vomiting this was day 3 (range 1-22), with a
median duration of 3 days (range 1-28). Five patients had to be
hospitalized for nausea/vomiting with a median hospitalization
duration of4 days (range 1-7). Nausea and vomiting were predom-
inantly grade I-II, and grade III-IV in 9% of cycles. Grade I-II
stomatitis was observed in 11% and grade I-II diarrhoea in 8% of
the cycles (grade III diarrhoea was reported in one case only). CTC
toxicity . grade I of ALAT, ASAT or bilirubin was observed in 87,
78, and 15 cycles respectively; toxicity . grade III was observed in
nine, two and one cycles respectively. Bilirubin grade IV toxicity
was observed in one patient with liver metastases and progressive
disease in cycle I. Maximum transient elevations of ASAT and
ALAT (64 and 71% ofcycles respectively) were observed on day 8,
lasting approximately one week (median day ofrecovery to normal
values for both ASAT and ALAT was day 15; range 8-26 for ASAT
and 8-36 forALAT). Three patients had theircycles delayed and/or
reduced owing to the persistence of grade I elevation of SGPT
value on day 28. No cumulative liver toxicity was observed. There
was no correlation between nausea/vomiting and liver toxicity or
tumour involvement ofthe liver.
Neither local phlebitis at the injection site nor renal or neuro-
toxicity were observed. Fatigue, considered as drug-related, was
common with grade I-III observed in 53% of cycles, including
grade III in 7% (Table 4). Nine patients had alopecia grade I or II
(11% of the cycles, with only one grade II). Cardiac toxicity was
evaluable in 26 patients who had their baseline echocardiography
or MUGA scan repeated after cycles 1-6. Two patients had to be
taken off-study because ofa decrease in LVEF (MUGA) of 215%.
One patient with head and neck cancer had a decrease in LVEF of
15% after three MMRDX cycles (cumulative dose 4.5 mg m-2
MMRDX). This patient had a history of rheumatic endocarditis.
He died 72 days after the last MMRDX dose as a result of a non-
cardiac condition. Post-mortem macro- and microscopic examina-
tion of the heart revealed no signs of cardiotoxicity. The second
patient (NSCLC) had a 17% decrease in LVEF (echocardiography)
after four cycles, with a cumulative dose of 6 mg m-2 MMRDX.
This patient had received previous radiotherapy to the medi-
astinum and had hypertension at baseline, both of which are
considered risk factors for anthracycline-related cardiotoxicity
(Minow et al, 1977). Measurements of LVEF after treatment
remained below the normal limit. One head and neck cancer
patient was taken off-study owing to atrial ectopic premature
beats, occurring at day 35 of cycle 2. LVEF of this patient
measured by echo remained above the normal limits (baseline
68%, off-study 72%).
Response
Forty-three patients were considered evaluable for tumour
response (at least two cycles of therapy received or early progres-
sion) (I18 renal cell cancer, 20 NSCLC, two head and neck cancer,
and two ACUP patients and one cervix carcinoma patient). Five
patients were not evaluable owing to tumour-related haemorrhage
(one patient), toxicity (three patients), and refusal (one patient).
One NSCLC patient with retroperitoneal metastases had a partial
response lasting 17 weeks. Stable disease was observed in 17
patients. Twenty-five patients had progressive disease.
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Pharmacokinetics
Pharmacokinetic sampling was performed in 17 patients. In 11
patients complete compartmental analysis was performed because
in these subjects blood was sampled according to the protocol.
Two subjects were excluded for compartmental analysis because
irregular plasma profiles prevented calculation of parameters. In
four subjects blood collection was only performed up to 24 h.
Average plasma concentrations vs time curve is shown in Fig. 2.
The MMRDX AUCo 0 using the linear trapezoidal rule was
20.4 ± 6.2 Htg x h 1-1 (n = 11). For all evaluable subjects, the three-
compartmental open model gave the best results. The distribution
of residuals and the coefficients of variation of the estimated para-
meters (< 30%) showed that the non-linear regression analysis was
satisfactory. The half-lives estimated for the three phases were
4 min, 2.4 and 49 h. The volume of the central compartment was
35 ± 33 1 m-2. Plasma clearance and volume of distribution at
steady-state were 37.2 ± 7.3 1 h-' m-2 and 1983 ± 6111 M-2. The
compartmental pharmacokinetic parameters of MMRDX are
summarized in Table 5. In the present study, the interindividual
coefficient of variation was about 20% on the basis of AUC calcu-
lated up to infinite time. The values of AUC0o24 h obtained in the
subjects for whom no further analysis was possible were in
reasonable agreement with those obtained in the other 11 subjects.
The AUC (0-24 h) for 13-dihydro metabolite was 2.5 ± 1.4 utg
x h 1- (n = 17) (12% of MMRDX AUC 0-24 h). Leucocyte
MMRDX levels (n = 6), expressed in MMRDX per 1 cell volume
[assuming 5.6 x 10"1 cells to be equal to 1 1 (Greidanus et al,
1989)] ranged from 218 to 1568 ,tg 1-1 (median 414 ,ug 1-1) at 2 h
and 50 to 347 ,ug 1-i (median 174 Htg 1-') at 24 h after infusion (Fig.
2). Mean leucocyte MMRDX concentrations 2 and 24 h after infu-
sion were 650- and 400-fold higher, respectively, than the corre-
sponding plasma concentrations. Intracellular levels of the
13-dihydro metabolite did not exceed 5% of total MMRDX
cellular levels. Urine collection up to 96 h was available in nine
patients. Urinary excretion of the unchanged drug accounted for
2.20 ± 0.76% ofthe administered dose; the compound is character-
ized by a renal clearance of about 1.8 1 h-'. The percentage urinary
excretion of 13-dihydro MMRDX was similar to that ofMMRDX.
No data on MMRDX binding to serum protein are available.
Pharmacodynamics
Pharmacodynamic analysis revealed no relationship between AUC
or Cmax and haematological or non-haematological toxicity. No
correlation between toxicity and leucocyte levels could be
observed.
DISCUSSION
This study describes the side-effects and anti-tumour activity
as well as the pharmacokinetics of MMRDX administered as
1.5 mg m-2 i.v. bolus every 4 weeks in patients with intrinsic resis-
tance to chemotherapy, including anthracyclines, and limited
pretreatment. Haematological toxicity was variable and character-
ized by a delayed neutrophil and platelet nadir with a tendency to
cumulative toxicity for platelets. This toxicity pattern is in accor-
dance with an earlier phase I study in which MMRDX was admin-
istered every 3 weeks as i.v. bolus in non-pretreated and heavily
pretreated solid tumour patients (Vasey et al, 1995). In that study, a
difference in neutrophil counts in pretreated patients compared
with untreated patients was reported. We observed bone marrow
toxicity grade IV in patients pretreated with chemotherapy as
radiosensitization. In our study, non-haematological toxicity
consisted mainly of late and prolonged nausea and vomiting,
despite an intensive prophylactic antiemetic regimen.
It is unclear why the onset of nausea and vomiting and, to a
lesser extent, bone marrow toxicity is late and its duration
prolonged. Lipophilicity of the drug with possibly peripheral
conversion to active metabolites could play a role. In the phase I
study of MMRDX, the same phenomenon was observed. Nausea
and vomiting could not be completely suppressed by the
antiemetic regimens. The degree of nausea and vomiting did not
correlate with elevations in liver function tests after treatment.
Central nervous system penetration, facilitated by the lipophilic
character of the drug or its metabolite(s), might be another poten-
tial underlying mechanism. There was a strikingly low incidence
of mucositis compared with other anthracyclines. Therefore,
gastric mucositis is probably not the underlying mechanism of
nausea and vomiting in this study. A more effective antiemetic
regimen has still to be defined. No clear signs of cardiotoxicity
were observed in our study or in the phase I study. However, as
cardiotoxicity is a late dose-limiting toxicity for classical anthra-
cyclines, prolonged monitoring is required to conclude that
MMRDX has a favourable profile. Repetitive treatment with
MMRDX only resulted in cumulative toxicity for platelets in the
26 patients who received three or more cycles.
In the present study, to test the preclinical finding of high effi-
cacy in drug resistant tumours we treated patients with intrinsic
anthracycline resistance. The response rate was, however, disap-
pointingly low (one in NSCLC out of 37 evaluable patients). In
NSCLC (20 evaluable patients) and renal cell cancer (18 evaluable
patients), MMRDX can be considered as ineffective. Efficacy of
MMRDX in head and neck tumour, cervical cancer and ACUP,
however, is as yet unclear because of the low patient numbers
treated so far. In the phase I study responses were observed in head
and neck and in cervical cancer (Vasey et al, 1995). Therefore,
evaluation of the efficacy of MMRDX in these tumour types may
still be interesting. We excluded patients older than 65 years and
patients with liver metastases from the pharmacokinetic study to
obtain uniformity of the pharmacokinetic data. By excluding a
substantial part of the included patients, caution is recommended
regarding the extrapolation of pharmacokinetic data to the whole
group of treated patients. Data from the patients studied, showed
that MMRDX has a high systemic clearance with a high volume
of the central compartment, which suggests rapid disposition
processes and higher volume of distribution at steady-state, which
indicates extensive distribution and binding to tissues. All these
results are in good agreement with data obtained in the phase I
study (Vasey et al, 1995). Low renal and high non-renal clearance
indicate that MMRDX is extensively excreted unchanged in the
bile and/or metabolized.
MMRDX, just as doxorubicin and epirubicin, showed a tri-
exponential plasma disappearance curve with a terminal half-life
similar to doxorubicin, whereas it is 1.6-fold higher than epiru-
bicin t/2,z (Camaggi et al, 1988). The MMRDX plasma clearance
is similar to that of doxorubicin, whereas that of epirubicin is
higher (Robert, 1993; Robert and Gianni, 1993), possibly indi-
cating the contribution of the glucuronidation pathway for this
anthracycline. MMRDX volume of distribution exceeded those of
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the other anthracyclines (Cersosimo and Hong, 1986; Mross et al,
1990; Plosker et al, 1993), probably as a result of its higher
lipophilicity. Peak cellular concentrations 0-48 h after simulta-
neous infusion of 20 mg of epirubicin and 20 mg of doxorubicin
were around 200 times higher than plasma concentrations of both
drugs (Tidefelt et al, 1989). Even higher (400- to 650-fold) cellular
MMRDX levels compared with plasma levels were observed in
our study. This is probably related to the high relative lipophilicity
of MMRDX that facilitates transport across membranes and rapid
cellular influx (Schwartz and Kanter, 1979). Pharmacodynamic
analysis of epirubicin and doxorubicin has revealed correlations
between AUC and haematological toxicity (Jakobsen et al, 1991;
Piscitelli et al, 1993). In this study, pharmacokinetic analysis was
performed in patients without liver metastases and < 65 years old.
The homogeneity of this small group of patients and the conse-
quent low interpatient variability probably contributed to the fact
that no correlation was observed between MMRDX pharmacoki-
netic data and toxicity. The present study showed a low response
rate in patients with the most unfavourable tumour types, namely
with intrinsic drug resistance. The high MMRDX tissue distribu-
tion and leucocyte levels indicates that morpholinyl anthracyclines
are still very interesting compounds in potentially more sensitive
tumour types. Results from further studies are eagerly awaited.
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